News

Amgen will summarize data from the submitted Biologic License Applications (BLAs) at a meeting with the FDA’s Advisory Committee for Reproductive Health Drugs (ACRHD). BLAs, for denosumab for

Skystar Bio-Pharmaceutical reports gross profit for the second quarter of $3.3m, up 42% from the second quarter of 2008. Gross margin for the quarter was 52.6%, compared to

Tianyin has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Sanqi Tablets in dosage form of 0.5gm/tablet, and Yinqiao Jiedu Tablets in dosage

Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has filed a patent for a novel composition and method for oral delivery of cobra venom, for

Celesio has reported an increase in revenue by 2% and EBITDA by 3.5% in local currency in the first half of 2009, as compared to the previous year.

Phase Forward has announced a multi-year, multi-million dollar extension of its existing partnership with CRO SGS. The agreement reinforces the companies’ close working relationship and offers SGS’s customers

OmniComm Systems has announced that it has been selected by a leading European Contract Research Organization (CRO), to provide eClinical solutions for a pivotal phase III study in

Verizon introduces two new capabilities designed to help safeguard the growing exchange of electronic patient data between hospitals, clinics, physicians, insurers and patients. The company claims that the

The Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a phase 2 clinical trial of Oncophage (vitespen), in combination with